Akebia Therapeutics
(NASDAQ) AKBA
Akebia Therapeutics Financials at a Glance
Market Cap
$278.99M
Revenue (TTM)
$232.40M
Net Income (TTM)
-$20.51M
EPS (TTM)
-$0.08
P/E Ratio
-13.47
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Price
$1.13
Volume
194,993
Open
$1.04
Price
$1.13
Volume
194,993
Open
$1.04
Previous Close
$1.13
Daily Range
$1.04 - $1.13
52-Week Range
$0.82 - $4.08
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.54 (High)
Price
$1.13
Volume
194,993
Open
$1.04
Previous Close
$1.13
Daily Range
$1.04 - $1.13
52-Week Range
$0.82 - $4.08
Estimated Earnings Date
Aug 6, 2026
AKBA News
AKBA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Akebia Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
194
CEO
John P. Butler, MBA
Website
www.akebia.comHeadquarters
Cambridge, MA 02142, US
AKBA Financials
Key Financial Metrics (TTM)
Gross Margin
80.87%
Operating Margin
2.28%
Net Income Margin
-8.83%
Return on Equity
-62.72%
Return on Capital
9.44%
Return on Assets
-5.66%
Earnings Yield
-7.42%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$278.99M
Shares Outstanding
268.26M
Volume
194.99K
Avg. Volume
4.38M
Financials (TTM)
Gross Profit
$187.95M
Operating Income
$5.29M
EBITDA
-$5.76M
Operating Cash Flow
$60.37M
Capital Expenditure
-$427.00K
Free Cash Flow
$60.01M
Cash & ST Invst.
$162.64M
Total Debt
$12.50M
Akebia Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$53.54M
-6.6%
Gross Profit
$40.93M
-17.7%
Gross Margin
76.43%
N/A
Market Cap
$278.99M
N/A
Market Cap/Employee
$1.54M
N/A
Employees
181
N/A
Net Income
-$9.05M
-248.1%
EBITDA
-$13.29M
-193.6%
Quarterly Fundamentals
Total Cash
$162.64M
+43.5%
Total Debt
$12.50M
-76.9%
Accounts Receivable
$62.54M
+1.6%
Inventory
$13.00M
-34.1%
Long Term Debt
$0.00
-100.0%
Short Term Debt
$12.50M
+126.6%
Return on Assets
-5.66%
N/A
Return on Invested Capital
2.80%
N/A
Free Cash Flow
-$21.21M
-55.9%
Operating Cash Flow
-$21.21M
-56.1%